ARGENX SE - ADR halted a late-stage study of its efgartigimod treatment for Sjögren's disease on Thursday morning after an interim review. The trial termination triggered a 16% share price drop, marking the company's steepest one-day decline in almost three years. European investors rushed to reprice the stock as a key rheumatology expansion avenue closed.

Clinical Trial Failure Hits Market Value